The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin,
levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity …

For 2 decades fluoroquinolones have been found to be generally well-tolerated and safe.
Adverse events may be inherent to the class or influenced by structural modifications. The …

Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial
comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of …

BACKGROUND: Premarketing trials showed the fluoroquinolone agents to have a favorable
side-effect profile, with treatment-related adverse events comprising gastrointestinal, central …

Study objectives: The etiologic role of bacterialpathogens isolated from sputum culture in 40
to 50% of acuteexacerbations of chronic bronchitis (AECB) is controversial. Ifbacterial …

More than a decade ago ciprofloxacin, the first quinolone with broad indications, was
released for clinical use in the United States. The release of ofloxacin, which also had broad …

A case-control study was conducted to identify the risk factors associated with levofloxacin-
resistant Streptococcus pneumoniae (LRSP) colonization or infection. Twenty-seven case …

Study objective To determine the steady-state plasma, epithelial lining fluid (ELF), and
alveolar macrophage (AM) concentrations of levofloxacin and ciprofloxacin. Design Multiple …

OBJECTIVE: This paper reviews the literature available on the new fluoroquinolones–
clinafloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin and …

In response to the overuse and misuse of antibiotics, leading to increasing bacterial
resistance and decreasing development of new antibiotics, the Council for Appropriate and …